Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.220
-0.060 (-1.83%)
Dec 5, 2025, 4:00 PM EST - Market closed
Grace Therapeutics Employees
Grace Therapeutics had 6 employees as of March 31, 2025. The number of employees increased by 2 or 50.00% compared to the previous year.
Employees
6
Change (1Y)
2
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,303,333
Market Cap
45.49M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GRCE News
- 19 days ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 23 days ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 25 days ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 6 weeks ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 2 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire
- 2 months ago - Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 - GlobeNewsWire